Entry Inhibitors of SARS-CoV-2 Targeting the Transmembrane Domain of the Spike Protein
Viruses · 2025
DOI: 10.3390/v17070989 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Kristin V Lyles und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Georgia State University, Atlanta, GA 35302, USA. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, SARS-CoV-2, Virus Internalization, Antiviral Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Despite current vaccines and therapeutics targeting SARS-CoV-2, the causative agent of the COVID-19 pandemic, cases remain high causing a burden on health care systems. Spike-protein mediated membrane fusion of SARS-CoV-2 is a critical step in viral entry. Herein, we describe entry inhibitors identified by first screening a library of about 160 compounds and then analogue synthesis. Specifically, compound 261 was found to inhibit SARS-CoV-2 infection in a tissue model with IC50 of 0.3 µM. Using NMR, we found that 261 interacts with key residues in the aromatic-rich region of the spike protein directly next to the transmembrane domain. Molecular dynamic simulations of the 261 binding pocket in the spike protein was also mapped to the transmembrane domain, consistent with NMR findings. The amino acids in the binding site are conserved among different coronaviruses known to infect humans; therefore, inhibitors targeting this conserved binding site could be a useful addition to current therapeutics and may have pan-coronavirus antiviral activities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Georgia State University, Atlanta, GA 35302, USA.
- Department of Biology, Georgia State University, Atlanta, GA 35302, USA.
- Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA 35302, USA.
- Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 35302, USA.
- Experimental Drug Development Centre (EDDC), Agency for Science, Technology, and Research (A*STAR), Singapore 138634, Singapore.
ORCID-Profile: Kristin V Lyles, Shannon Stone, Lila D Patterson, Amany Elsharkawy, Dongning Liu, Shubham Bansal, Congbao Kang, Binghe Wang, Mukesh Kumar, Ming Luo
Förderung
- NIGMS NIH HHS
- NIH HHS
- NIAID NIH HHS
- NIH
Zitieren
APA
Lyles, K. V., Stone, S., Singh, P., Patterson, L. D., Natekar, J., Pathak, H., Varshnaya, R. K., Elsharkawy, A., Liu, D., Bansal, S., Faniyi, O. O., Tang, S., Yang, X., Mulpuri, N., Hamelberg, D., Kang, C., Wang, B., Kumar, M., & Luo, M. (2025). Entry Inhibitors of SARS-CoV-2 Targeting the Transmembrane Domain of the Spike Protein. Viruses. https://doi.org/10.3390/v17070989
Vancouver
Lyles KV, Stone S, Singh P, Patterson LD, Natekar J, Pathak H, et al. Entry Inhibitors of SARS-CoV-2 Targeting the Transmembrane Domain of the Spike Protein. Viruses. 2025. doi:10.3390/v17070989
BibTeX
@article{Lyles2025,
author = {Lyles, Kristin V and Stone, Shannon and Singh, Priti and Patterson, Lila D and Natekar, Janhavi and Pathak, Heather and Varshnaya, Rohit K and Elsharkawy, Amany and Liu, Dongning and Bansal, Shubham and Faniyi, Oluwafoyinsola O and Tang, Sijia and Yang, Xiaoxiao and Mulpuri, Nagaraju and Hamelberg, Donald and Kang, Congbao and Wang, Binghe and Kumar, Mukesh and Luo, Ming},
title = {Entry Inhibitors of SARS-CoV-2 Targeting the Transmembrane Domain of the Spike Protein},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17070989}
}
EUVIMED